Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717533 · ClinicalTrials.gov registry record
Blood Volume Analysis and Renal Outcomes in Hemodialysis
A clinical trial of Kidney Failure and End Stage Renal Failure on Dialysis, sponsored by VA New York Harbor Healthcare System.
- Completed
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT02717533: Completed study of Kidney Failure and End Stage Renal Failure on Dialysis, sponsored by VA New York Harbor Healthcare System.
NCT02717533 is a study of Kidney Failure and End Stage Renal Failure on Dialysis that has completed, run by VA New York Harbor Healthcare System. The registered enrollment target is 12 participants, below the 587-participant average among 18 other Kidney Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02717533, a study of Kidney Failure and End Stage Renal Failure on Dialysis, has completed, sponsored by VA New York Harbor Healthcare System.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the proposed study is to demonstrate that serial blood volume analysis (BVA) using RI-BVA (BVA-100, Daxor, NY) can be used to guide changes in prescription of dry weight for hemodialysis patients. The knowledge of a patient's ideal BV and degree of hypervolemia using these measurements can be used to change the prescription of DW in an objective way instead of the current standard of practice, which is based on subjective prescription of dry weight. A first study was conducted to determine the rate of plasma volume (PV) re-expansion for each patient as a guide to rate of fluid removal (results published, refer to citations). A second study was conducted in order to assess the value of a BVA measurement in guiding prescription of clinical DW. A follow up BVA would then be done in order to check if patients were closer to ideal BV than prior to changing dry weight.
Primary Outcome
To demonstrate that serial BVA using the Blood Volume Analyzer (BVA-100) can be used to guide changes in prescription of DW for HD patients in an objective way instead of the current standard of practice, which is based on subjective prescription of dry weight. The results obtained from this first study have been published (see references) and show good correlation with CLM-III measurements and can estimate individual refilling ability
Conditions Studied
Interventions
- OTHER dry weight adjustment
Study Locations (1)
New York
- New York Harbor VA Healthcare System Hemodialysis Unit - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-01 |
What the finished NCT02717533 record still lists
NCT02717533 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 587-participant average among 18 other Kidney Failure trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Kidney Failure appearing as the primary indexed condition, and to 1 intervention - of which dry weight adjustment is the first listed.
NCT02717533 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02717533 about?
NCT02717533 is a clinical study titled "Blood Volume Analysis and Renal Outcomes in Hemodialysis". The objective of the proposed study is to demonstrate that serial blood volume analysis (BVA) using RI-BVA (BVA-100, Daxor, NY) can be used to guide changes in prescription of dry weight for hemodialysis patients. The knowledge of a patient's ideal BV and degree of hypervolemia using these measureme...
What is the current status of trial NCT02717533?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2014-01. Estimated completion is 2015-01.
What conditions does trial NCT02717533 study?
This clinical trial studies the following conditions: Kidney Failure, End Stage Renal Failure on Dialysis, Actual Impaired Fluid Volume.
What interventions are being tested in trial NCT02717533?
The interventions under investigation include: dry weight adjustment (OTHER).
Who is sponsoring clinical trial NCT02717533?
This trial is sponsored by VA New York Harbor Healthcare System, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02717533 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02717533's enrollment target sits among peer trials
12 16th of 18 higher than 1 of 18 other Kidney Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerance Through Mixed Chimerism (Sip-Tego)
RECRUITING · Early Phase 1
-
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
RECRUITING · Phase 1
-
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
RECRUITING
-
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
RECRUITING · NA
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia